• Press
  • Offices
  • Contact
  • Legal notice
  • EN
    • DE
  • UPC
  • Firm
    • Main Focus
    • History
    • Guiding Principle
    • Awards and Rankings
  • Our Practice
    • Legal Areas
    • Industries
  • Our Team
  • Career
    • Working with us
  • News & Knowledge
    • News
    • Events
    • UPC-Update
    • IP-Update
    • Brexit-Update
    • Publications
    • B&B Bulletin
  • Menu Menu
FIND EXPERTS
  • UPC
  • Firm
    • Main Focus
    • History
    • Guiding Principle
    • Awards and Rankings
  • News & Knowledge
    • News
    • Events
    • UPC-Update
    • IP-Update
    • Brexit-Update
    • Publications
    • B&B Bulletin
  • FIND EXPERTS
  • Contact
  • Our Practice
    • Legal Areas
    • Industries
  • Our Team
  • Career
    • Working with us
  • Offices
  • EN
    • DE

Breaking: Broad Institutes CRISPR/Cas9 Gene Editing patent finally revoked in Europe!

17. January 2020/in IP-Update

Yesterday, on January 16, 2020, the Board of Appeal in the opposition proceedings for revocation of the European patent No. EP 2 771 468, Broad Institutes initial patent claiming the gene editing approach in mammalian cells, has been revoked after 4 days of intensive proceedings at the European Patent Office (EPO) in Munich.

Nine opponents had filed oppositions against the grant of the CRISPR patent, and the appeal proceedings had been initiated by the Broad Institute after a first instance decision to revoke the patent in its entirety as not novel because of a defect in the priority claim. The Technical Board of Appeal yesterday confirmed the first instance decision surprisingly; since the day before it had indicated its preliminary inclination to refer this case to the Enlarged Board of Appeal – the highest judicial body at the EPO. However, after yesterday’s pleadings, apparently, the Technical Board changed its mind in a dramatic reversal of its previous announcements and dismissed the appeal. The patent remains revoked; the decision is final and cannot be contested for substantive reasons.

While a disaster for the Broad Institutes CRISPR patent portfolio, the decision will render development and business in the gene editing field in Europe possibly easier. From a legal point of view, the decision again confirms the long standing practice of the EPO to demand identity between the applicant of the priority application and the subsequent application, or an impeccable chain of transfer of the original priority rights to the non-identical applicant of the later application. This underlines the complexity and importance of establishing a correct priority claim under European law.

/wp-content/uploads/2022/04/boehmert_logo.svg 0 0 Petra Hettenkofer /wp-content/uploads/2022/04/boehmert_logo.svg Petra Hettenkofer2020-01-17 00:00:002022-08-02 17:12:46Breaking: Broad Institutes CRISPR/Cas9 Gene Editing patent finally revoked in Europe!

Author

Dr. Markus Engelhard
Dr. Ute Kilger
Dr. Jan B. Krauß
Dr. David Kuttenkeuler

Contents

More articles

  • Termination of the Swiss-German Agreement of 1892 - what… 23. May 2022
  • ECJ declares German court practice regarding the… 2. May 2022
  • Intellectual property updates in light of the ongoing war in… 26. April 2022

Menu

  • Firm
  • Our Practice
  • Career
  • News & Knowledge
  • FIND EXPERTS

Informations

  • Press
  • Contact
  • Legal notice
  • Data Protection
  • General Terms and Conditions
  • Contact

Legal Areas

  • Employee Inventions
  • Data Protection
  • Designs
  • Domains
  • Information Technology
  • Anti-Trust
  • Licencing
  • Trade Marks
  • Patent Valuation
  • Patents & Utility Models
  • Patent Litigation
  • Product Piracy
  • Copyright
  • Unfair Competition

© Copyright 2023– BOEHMERT & BOEHMERT

Scroll to top

We only use functional cookies and no third party services. Learn more in our privacy policy.

Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.